The following are selected life science industry transactions and financings that were executed by senior members of the Firm.
Alteon: Acted as advisor to Alteon, a cardiovascular biotechnology company in its merger with HaptoGuard, a privately-held biotechnology company.
Baxter: Acted as advisor to Baxter in its spinoff of Allegiance, a medical products manufacturer and distributor.
Bayer AG: Acted as advisor to Bayer Corporation in the sale of ChemDesign Corporation, a fine chemical company, to Chestnut Investments LLC.
Boston Scientific: Acted as advisor to Boston Scientific in its $1.1 billion acquisition of Target Therapeutics a maker of implantable neurovascular devices.
Bristol-Myers Squibb: Acted as advisor to Bristol-Myers Squibb in its partial acquisition of ImClone Systems and its partnering of Erbitux, an oncology product
Caliper Life Sciences: Acted as advisor to Caliper Life Sciences, the leading microfluidics company, in its acquisition of NovaScreen, a life science services company.
Chirex: Co-managed the $87 million IPO of this pharmaceutical and intermediates company.
Genzyme Corporation: Acted as advisor to Genzyme Corporation in the sale of its Genzyme Pharmaceutical Ingredients Business in Switzerland to International Chemical Investors Group (ICIG).
Leiner Health Products: Acted as advisor to AEA Investors, majority shareholder of Leiner in the sale of the private label vitamin and supplement producer to North Castle Partners in a $300 million leveraged recapitalization.
Lipella Pharmaceuticals Completed a corporate business and regulatory strategy review, including assessing strategic/financial alternatives
LKC Technologies: Acted as placement agent for private placement of securities for this retinal diagnostics company.
Luminex: Co-managed the $85 million IPO of this developer of bioassays for the life science industry.
Merck KGaA: Acted as advisor to Merck KGaA in its acquisition of the 51% of VWR Scientific, a distributor of laboratory products and supplies, from the public for $575 million.
Nanogen: Co-managed the $43 million IPO of this developer of microarray diagnostic testing systems.
Nexell Therapeutics: Acted as private placement agent for a $63 million offering of convertible notes backed by Baxter.
NPS Pharmaceuticals: Acted as advisor to NPS Pharmaceuticals in its outlicensing of Gattex, a Phase 3 gastrointestinal product to Nycomed for $35 million upfront and $500 million in milestone payments.
Nutrition 21: Acted as co-placement agent in $10 million PIPE financing for Nutrition 21, a supplier of nutritional supplements.
ÖMV: Acted as advisor in the sale of ÖMV’s fine chemical division, Chemie Linz, located in Austria, to DSM for 2.2 billion schillings
Paratek Pharmaceuticals: Acted as advisor to Paratek with regard to a review of its strategic, regulatory and financial alternatives
Perkin-Elmer Corporation: Acted as advisor to the Perkin-Elmer Corporation in the sale of PerSeptive Biosystems GmbH-Hamburg to a subsidiary of SKW Trostberg AG.
Pharmacia & Upjohn: Acted as advisor to Pharmacia & Upjohn in the renegotiation of its licensing agreement with Miravant Medical Technologies relating to its ophthalmology compounds.
Phyto-Source L.P.: Advised the shareholders of Phyto-Source, a leading supplier of phytosterols, in the sale of the business to Cognis.
Proquest: Acted as co-lead placement agent for Proquest, an oncology-focused venture capital fund.
Regeneration Technologies: Co-managed the $75 million IPO of this producer of orthopedic products using allograft tissue .
Sanofi: Acted as advisor to Sanofi in the sale of its Parental Products business to Abbott Laboratories for $200 million.
Schering AG: Acted as advisor to Schering in the defense of a hostile offer from Merck KGaA and subsequent sale to Bayer fro $20.5 billion.
Schick Technologies: Acted as advisor to Schick Technologies in the sale of the digital dental radiography company to Sirona Dental.
SmithKline Beecham: Acted as advisor to SmithKline Beecham in the acquisition of Block Drug, a consumer products company, for $1.2 billion.
Synthon Chiragenics: Acted as advisor to Synthon Chiragenics in the sale of its Fine Chemicals business and the license of certain technology rights to Avecia Ltd.
Teva Pharmaceutical: Acted as advisor to Teva Pharmaceutical in its acquisition of generic drug maker Biocraft Laboratories for $356 million.
Thoratec: Acted as advisor to Thoratec in its acquisition of Thermo Cardiosystems, a maker of cardiovascular devices, for 460 million.
Versicor: Acted as advisor to Versicor in its merger with Biosearch Italia in a $261 million transaction to form Vicuron Pharmaceuticals, an anti-infectives company.